TY - JOUR
T1 - Effects of fluoxetine on the polysomnogram in outpatients with major depression
AU - Trivedi, Madhukar H.
AU - Rush, A. John
AU - Armitage, Roseanne
AU - Gullion, Christina M.
AU - Grannemann, Bruce D.
AU - Orsulak, Paul J.
AU - Roffwarg, Howard P.
N1 - Funding Information:
The authors wish to express their appreciation to John R. Debus, M.D., Jeff Bostic, M.D., Terry Cook, L.V.N., and David Dunnam, B.S., for assistance with data collection; Darwynn Cole, and the technical staff of the Sleep Study Unit; to Fastword Inc., of Dallas, David Savage and Theresa Ranne, for their secretarial assistance; and to Kenneth Z. Altshuler, M.D., Stanton Sharp Distinguished Chair, Professor and Chairman, for his administrative support. This study was supported in part by a contract from Eli Lilly and Company and a grant from the National Alliance for Research in Schizophrenia and Depression (Dr. Trivedi).
PY - 1999/5
Y1 - 1999/5
N2 - This study investigated the effects of open-label fluoxetine (20 mg/d) on the polysomnogram (PSG) in depressed outpatients (n = 58) who were treated for 5 weeks, after which dose escalation was available (≤40 mg/d), based on clinical judgment. Thirty-six patients completed all 10 weeks of acute phase treatment and responded (HRS-D≤ 10). PSG assessments were conducted and subjective sleep evaluations were gathered at baseline and at weeks 1, 5, and 10. Of the 36 subjects who completed the acute phase, 17 were reevaluated after 30 weeks on continuation phase treatment and 13 after approximately 7 weeks (range 6-8 weeks) following medication discontinuation. Acute phase treatment in responders was associated with significant increases in REM latency, Stage 1 sleep, and REM density, as well as significant decreases in sleep efficiency, total REM sleep, and Stage 2 sleep. Conversely, subjective measures of sleep indicated a steady improvement during acute phase treatment. After fluoxetine was discontinued, total REM sleep and sleep efficiency were found to be increased as compared to baseline. Copyright (C) 1999 American College of Neuropsychopharmacology.
AB - This study investigated the effects of open-label fluoxetine (20 mg/d) on the polysomnogram (PSG) in depressed outpatients (n = 58) who were treated for 5 weeks, after which dose escalation was available (≤40 mg/d), based on clinical judgment. Thirty-six patients completed all 10 weeks of acute phase treatment and responded (HRS-D≤ 10). PSG assessments were conducted and subjective sleep evaluations were gathered at baseline and at weeks 1, 5, and 10. Of the 36 subjects who completed the acute phase, 17 were reevaluated after 30 weeks on continuation phase treatment and 13 after approximately 7 weeks (range 6-8 weeks) following medication discontinuation. Acute phase treatment in responders was associated with significant increases in REM latency, Stage 1 sleep, and REM density, as well as significant decreases in sleep efficiency, total REM sleep, and Stage 2 sleep. Conversely, subjective measures of sleep indicated a steady improvement during acute phase treatment. After fluoxetine was discontinued, total REM sleep and sleep efficiency were found to be increased as compared to baseline. Copyright (C) 1999 American College of Neuropsychopharmacology.
KW - Depression
KW - Fluoxetine
KW - REM sleep
KW - Sleep EEG
UR - http://www.scopus.com/inward/record.url?scp=0033136172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033136172&partnerID=8YFLogxK
U2 - 10.1016/S0893-133X(98)00131-6
DO - 10.1016/S0893-133X(98)00131-6
M3 - Article
C2 - 10192825
AN - SCOPUS:0033136172
SN - 0893-133X
VL - 20
SP - 447
EP - 459
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 5
ER -